On November 14, 2018, Virta Health announced a new, at-risk diabetes management model for type 2 diabetes, linking payment to clinical outcomes. In the new reimbursement model, Virta Health is paid only if consumers are engaged after one month, and again after a year if the consumers lower their HbA1C blood glucose level to targets determined on a case-by-case basis. The targets will indicate reversal of type 2 diabetes. Virta is marketing its services to self-insured employers and health plans. Reversal is defined as the percentage of consumers with HbA1c less than 6.5% who are . . .